Bellerophon Therapeutics, Inc. (BLPH)
Chart Events
Performance Outlook
| Previous Close | 1.2300 |
| Open | 1.1900 |
| Bid | 1.0600 x 1800 |
| Ask | 1.2300 x 1200 |
| Day's Range | 1.1500 - 1.2100 |
| 52 Week Range | 0.6700 - 4.9800 |
| Volume | |
| Avg. Volume | 63,208 |
| Market Cap | 11.168M |
| Beta (5Y Monthly) | -0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8850 |
| Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BLPH
Related Research
- Bellerophon Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 06/23/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat10 days agoArgus Research
- GlobeNewswire
Bellerophon Announces Poster Presentation at Upcoming American Thoracic Society 2022 International Conference
WARREN, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced a poster presentation at the upcoming American Thoracis Society (ATS) 2022 International Conference, being held May 13-18, 2022, in San Francisco, CA. Presentation Details Session C103: It's not just about IPFPoster Title: A Phase 2 Trial of INOpulse in
- GlobeNewswire
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the first quarter ended March 31, 2022. “We remain focused on the continued advancement of our late-stage INOpulse® inhaled nitric oxide therapy platform for the treatment of fibrotic interstit
- GlobeNewswire
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2021. “The development of our INOpulse® inhaled nitric oxide therapy platform remains our foremost priority, in order to address the significant unmet needs in fib
